Clinical trials: Immunity, Mucosal
Viral Infections
A Study of Intranasal LMN-1001 in Healthy Adults
The purpose of this study is to optimize the tolerability of LMN-1001 relative to its ability to activate the host immune response. LMN-1001 is an investigational dry powder containing recombinant interferon lambda (IFN-λ).
- Trial name
- NCT07852208
- Testing
- LMN-1001
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Irritable Bowel Syndrome (IBS)
Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients
The study is a randomised, placebo-controlled, double-blind parallel study in IBS patients. A total of 60 adult patients diagnosed with IBS-C, -D or -A/M according to Rome IV criteria will be included.
- Trial name
- NCT02875847
- Testing
- HMO1, HMO2, Dextropur
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Glycom A/S
COVID-19
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for successive waves, is to better understand and diagnose the infection.
- Trial name
- COVARIANT (NCT05858502)
- Testing
- Blood sample collection, Saliva sample collection, Nasopharyngeal and nasal sample collection
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Immune Function, Immunity
Effects of TM02® Supplementation on Immune Function in Children
This randomized, double-blind, placebo-controlled clinical study evaluated the effects of 12 weeks of TM02® supplementation on immune-related outcomes in generally healthy children aged 2 to 12 years.
- Trial name
- NCT07853573
- Testing
- TM02®
- Where
- Malaysia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Ligno Biotech Sdn. Bhd.
Cutaneous Melanoma, Mucosal Melanoma
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
- Trial name
- NCT07600476
- Testing
- KUP-101A
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kupando GmbH
HIV Infections, HIV Seronegativity
A Study of GENEVAX-HIV, a Possible Vaccine
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug…
- Trial name
- NCT00002232
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
Influenza, Orthomyxovirus Infections
Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines
To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations.
- Conditions
- Influenza, Orthomyxovirus Infections, Myxovirus Infection
- Trial name
- NCT00776438
- Testing
- Inactivated, split-virion, influenza vaccine, Inactivated, split-virion influenza vaccine
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Inflammatory Bowel Disease
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
The primary purpose of this study is to determine the rates of seroconversion to a hepatitis B vaccine series after a single 750 mg intravenous (IV) dose of vedolizumab or placebo.
- Trial name
- NCT01981616
- Testing
- Vedolizumab, Hepatitis B vaccine, Oral cholera vaccine
- Where
- United Kingdom
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.